The pharmaceutical company EntreMed has announced a Phase 2 study of ENMD-2076 in triple-negative breast cancer.  

Jennifer R. Diamond, MD, of the University of Colorado, says, 

"We are encouraged by the data from the Phase 1 study of ENMD-2076 in patients with advanced solid tumors, including triple-negative breast cancer. ENMD-2076 has also demonstrated significant anti-tumor activity against preclinical models of breast cancer with more robust activity against triple-negative breast cancer alone or in combination with standard chemotherapies. This single-agent Phase 2 study is designed to determine the activity of ENMD-2076 by the clinical benefit rate in patients with previously treated locally advanced or metastatic triple-negative breast cancer."

For more information, check out the news release.